On February 8, 2019, Gossamer Bio listed on Nasdaq under the ticker “GOSS.” The Hillhouse-backed biotech company raised $276 million in proceeds, and the company saw very healthy interest from investors.

Proceeds from the listing were planned to be used to continue funding Gossamer’s innovative product pipeline.